Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05271604 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by BioAtla.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT05271604 is a Phase 2 study that has completed, run by BioAtla. The registered enrollment target is 42 participants.
The verdict
NCT05271604, a Phase 2 study, has completed, sponsored by BioAtla.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Cetuximab
- BIOLOGICAL Ozuriftamab Vedotin
- BIOLOGICAL Evalstotug (BA3071)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2025-09-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05271604
The ClinicalTrials.gov registry entry for NCT05271604 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05271604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05271604 about?
NCT05271604 is a clinical study titled "A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck". This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT05271604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2022-12-13. Estimated completion is 2025-09-22.
What interventions are being tested in trial NCT05271604?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cetuximab (BIOLOGICAL), Ozuriftamab Vedotin (BIOLOGICAL), Evalstotug (BA3071) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05271604?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.